Pharmaceuticals - Sudan

  • Sudan
  • The Pharmaceuticals market in Sudan is expected to witness a significant growth in revenue, with projections indicating that it will reach US$258.40m in 2024.
  • among the various markets of the market, Oncology Drugs stands as the largest market, with a projected market volume of US$10.59m in 2024.
  • This signifies the growing importance of oncology drugs in the country's pharmaceutical landscape.
  • Furthermore, the revenue in the Pharmaceuticals market is anticipated to display a steady annual growth rate of -2.27%, as per the compound annual growth rate (CAGR) estimated for the period 2024-2029.
  • This growth trajectory is expected to result in a market volume of US$230.40m by 2029.
  • These statistics highlight the positive outlook and potential for expansion within Sudan's pharmaceutical market.
  • When comparing in Sudan to the global pharmaceutical market, it is worth noting that United States is projected to generate the highest revenue, amounting to US$630.30bn in 2024.
  • This stark contrast emphasizes the dominance of the US market on a global scale, while also highlighting the potential for further growth and development within Sudan's pharmaceutical sector.
  • Sudan's pharmaceutical market is experiencing a surge in demand for essential medicines due to increasing healthcare awareness and a growing population.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Pharmaceuticals market in Sudan has been steadily growing in recent years, driven by several factors that are unique to the country.

Customer preferences:
Sudan has a large population that is increasingly becoming health-conscious and seeking better access to healthcare services. This has led to a growing demand for pharmaceutical products, particularly those that treat chronic diseases such as diabetes and hypertension.

Trends in the market:
One of the key trends in the pharmaceuticals market in Sudan is the increasing adoption of generic drugs. This is due to the fact that generic drugs are more affordable than their branded counterparts, making them more accessible to a larger segment of the population. Additionally, the government has implemented policies to encourage the use of generic drugs, which has further boosted their popularity in the country. Another trend that is shaping the pharmaceuticals market in Sudan is the increasing use of technology in healthcare. This includes the use of telemedicine and mobile health apps, which are helping to improve access to healthcare services in remote areas of the country. This trend is likely to continue as the government invests in improving healthcare infrastructure and promoting the use of technology in healthcare.

Local special circumstances:
Sudan has a challenging business environment, with a high level of political and economic instability. This has made it difficult for pharmaceutical companies to operate in the country, particularly those that rely on imports of raw materials and finished products. Additionally, the country has a weak regulatory environment, which has led to concerns about the quality and safety of pharmaceutical products on the market.

Underlying macroeconomic factors:
The Sudanese economy has been struggling in recent years, due to a combination of factors including political instability, economic sanctions, and the impact of COVID-19. This has led to a depreciation of the Sudanese pound, which has made it more expensive for pharmaceutical companies to import raw materials and finished products. Additionally, the country has a large informal economy, which has made it difficult for the government to collect taxes and regulate the pharmaceutical market effectively. In conclusion, while the pharmaceuticals market in Sudan is growing, it is facing several challenges that are unique to the country. These include a weak regulatory environment, a challenging business environment, and an unstable macroeconomic situation. However, the increasing adoption of generic drugs and the use of technology in healthcare are positive trends that are likely to continue to shape the market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)